PAMELA ALFAFARA: Open Payments
NPI 1558387985 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,099 in 42 payments from 14 companies in 2025. Trend: 2023 $1,298 · 2024 $1,021 · 2025 $1,099
Food & beverage: $1,099
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 7 | $175 |
| Neurocrine BioSciences, Inc. | 6 | $157 |
| Teva Pharmaceuticals USA, Inc. | 4 | $125 |
| Lundbeck LLC | 4 | $114 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $113 |
| Janssen Pharmaceuticals, Inc | 3 | $82 |
| Axsome Therapeutics, Inc. | 2 | $65 |
| Biogen, Inc. | 2 | $60 |
| Collegium Pharmaceutical, Inc. | 2 | $49 |
| ABBVIE INC. | 3 | $46 |
Products named: COBENFY, INGREZZA, REXULTI, AUSTEDO XR, CAPLYTA, Auvelity, ZURZUVAE, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
